Beyond Air, Inc.(XAIR)Earnings, Financials & Key Ratios
XAIR•NASDAQ
$0.48
Price updated Jun 25, 2026
AboutBeyond Air, Inc. operates as a commercial medical device and biopharmaceutical company. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.Show more
- Revenue$4M+219.7%
- EBITDA-$41M+32.5%
- Net Income-$47M+22.6%
- EPS (Diluted)-13.77+62.1%
- Gross Margin-44.89%+60.2%
- EBITDA Margin-1105.7%+78.9%
- Operating Margin-1202.08%+77.9%
- Net Margin-1258.43%+75.8%
- ROE-224.55%-29.0%
XAIR Price & Volume
Beyond Air, Inc. (XAIR) stock price & volume — 10-year historical chart
Loading chart...
Accelerating Revenue Growth Faces Severe Liquidity Constraints
Investment Thesis • Updated 2026Q4
VerdictNegative: The company faces imminent liquidity risks with only $6.7M in cash remaining against a quarterly net loss of $10.3M
Growth:Accelerating
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and dilution
Key Thesis Takeaways
- Beyond Air is currently navigating a critical transition phase as it scales the LungFit PH platform, evidenced by a 65.5% year-over-year revenue growth rate in 2026Q4.
- However, the company's fundamental outlook remains challenged by persistent operating losses of $10.3M and a rapidly depleting cash position of $6.7M.
- Investors should monitor the company's ability to achieve sustainable gross margins, which currently hover at a volatile 4.9%, against the backdrop of significant dilution risks required to fund ongoing R&D and commercial infrastructure.
Verdict Logic
suggesting a high probability of further dilutive capital raises.
XAIR Growth Metrics
Beyond Air, Inc. (XAIR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years21.66%
3 Years-
TTM129.04%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM40.72%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM74.3%
Return on Capital
10 Years-134.37%
5 Years-95.13%
3 Years-111.9%
Last Year-126.43%
Peers Comparison
Key metrics vs top competitors for Beyond Air, Inc. (XAIR)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.48 | $4.01M | -0.03 | 219.67% | -1258.43% | -224.55% | — | |
| $23.35 | $1.72B | 7.08 | 18.52% | 118.91% | 47.59% | — | |
| $104.47 | $22.64B | -16.30 | 66.73% | -144.44% | -130.11% | — | |
| $327.99 | $9.47B | -24.33 | -100% | — | -43.02% | — | |
| $62.03 | $1.21B | -6.38 | -43.89% | -284.18% | -87% | — | |
| $10.35 | $2.19B | 69.00 | 26.93% | 10.51% | 10.2% | — |
Compare XAIR vs Peers
Beyond Air, Inc. (XAIR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when XAIR posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
XAIR Frequently Asked Questions
Beyond Air, Inc. (XAIR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Beyond Air, Inc.'s revenue?
Beyond Air, Inc. (XAIR) reported $6.9M in revenue for fiscal year 2025.
How fast is Beyond Air, Inc. growing?
Beyond Air, Inc. (XAIR) grew revenue by 219.7% over the past year. This is strong growth.
Is XAIR profitable?
Beyond Air, Inc. (XAIR) reported a net loss of $31.0M for fiscal year 2025.
Dividend & Returns
What is XAIR's return on equity?
Beyond Air, Inc. (XAIR) has a return on equity (ROE) of -224.6%. Negative ROE indicates the company is unprofitable.
What is Beyond Air, Inc.'s free cash flow?
Beyond Air, Inc. (XAIR) had negative free cash flow of $22.1M in fiscal year 2025, likely due to heavy capital investments.